RALA抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using RALA mouse mAb against HepG2 (1), MCF-7 (2), A549 (3), K562 (4), Raji (5), MOLT4 (6), Hela (7), COS7 (8), and NIH3T3 (9) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using RALA mouse mAb (green) and negative control (red).    

  
  

RALA (RAS-like proto-oncogene A), a member of the RAS GTPase superfamily, plays critical roles in regulating cellular processes such as vesicle trafficking, cytoskeletal organization, and signal transduction. As a small GTPase, it cycles between an active GTP-bound state and an inactive GDP-bound state, acting as a molecular switch to control downstream pathways. Dysregulation of RALA has been implicated in various diseases, including cancer, where its overexpression or hyperactivation promotes tumor progression, metastasis, and therapy resistance.

RALA-specific antibodies are essential tools for studying its expression, localization, and activation dynamics. These antibodies often target distinct epitopes, such as conserved regions or phosphorylation sites (e.g., Ser194), to differentiate between active and inactive states. They enable applications like Western blotting, immunofluorescence, and flow cytometry, aiding in the exploration of RALA's role in cellular contexts. Recent studies also highlight RALA's involvement in neurological disorders and metabolic syndromes, expanding its relevance beyond oncology.

The development of high-affinity, isoform-selective RALA antibodies remains a priority, as cross-reactivity with homologous proteins (e.g., RALB) can complicate data interpretation. Advances in antibody engineering, including monoclonal and phospho-specific variants, continue to enhance precision in both basic research and therapeutic targeting, particularly in personalized medicine approaches for RALA-driven pathologies.